Earnings Releases·Nov 12, 2026, 8:01 AM ET

Grace Therapeutics — Second Quarter 2027 Earnings Summary

Reported a net loss of $2.1 million ($0.11 per share) for the three months ended September 30, 2026, widening from $0.9 million ($0.06 per share) in the prior year period, driven by a $0.3 million increase in R&D expenses offset by a $0.6 million decrease in general and administrative expenses.
Completed a $10 million private placement in August 2026, raising net proceeds of $9.2 million to fund manufacturing and regulatory activities, bringing cash and cash equivalents to $21.3 million as of September 30, 2026.
Cash reserves are projected to sustain operations through the end of 2028 while executing a plan to address FDA Complete Response Letter items for GTx-104, including initiating non-clinical studies and advancing a dual-source manufacturing strategy.
NDA resubmission timing remains contingent on resolving CMC and non-clinical data items, with the launch date dependent on whichever manufacturing site (current or dual-source) achieves readiness first.